Sporos Bioventures Logo

Lauren Hopfer

Sporos BioDiscovery to Present Preclinical Findings on SPR1, a Next-Generation TEAD Inhibitor, at the American Association for Cancer Research (AACR) Annual Meeting 2023

Press Releases / By

HOUSTON, Texas., March 15, 2023 — Sporos BioDiscovery, Inc. (a wholly owned affiliate of Sporos Bioventures, “Sporos” or the “Company”), a precision oncology company developing a diversified pipeline of small molecule therapeutic programs targeting cancer vulnerabilities in the tumor and tumor microenvironment, today announced that it will present a poster highlighting preclinical data from the …

Sporos BioDiscovery to Present Preclinical Findings on SPR1, a Next-Generation TEAD Inhibitor, at the American Association for Cancer Research (AACR) Annual Meeting 2023 Read More »

Sporos BioDiscovery Presents Preclinical Data on Differentiated TEAD Inhibitor Program, SPR1, at the 34th EORTC-NCI-AACR Symposium

Press Releases / By

SPR1 Demonstrates Single Agent Anti-Tumor Activity in vivo, Achieving Regression in Established, Large Volume Tumors SPR1 Synergizes with MAPK Inhibitors and Upstream Activators of the MAPK Pathway HOUSTON, Texas., October 26, 2022 — Sporos BioDiscovery, Inc. (a wholly owned affiliate of Sporos Bioventures, “Sporos” or the “Company”), a precision oncology company developing a diversified pipeline …

Sporos BioDiscovery Presents Preclinical Data on Differentiated TEAD Inhibitor Program, SPR1, at the 34th EORTC-NCI-AACR Symposium Read More »

FDA Grants Fast Track Designation to Tvardi Therapeutics’ TTI-101 for Hepatocellular Carcinoma

Press Releases / By

Houston, TX – October 19, 2022 – Tvardi Therapeutics, Inc. (“Tvardi”), a privately held, clinical-stage biopharmaceutical company focused on the development of STAT3 inhibitors, today announced that its lead product, TTI-101, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of relapsed/refractory locally advanced, unresectable, or metastatic …

FDA Grants Fast Track Designation to Tvardi Therapeutics’ TTI-101 for Hepatocellular Carcinoma Read More »

Tvardi Therapeutics’ TTI-101 Receives Orphan Drug Designation for Idiopathic Pulmonary Fibrosis

Press Releases / By

Houston, TX – May 26, 2022 – Tvardi Therapeutics, Inc. (“Tvardi”), a privately held, clinical-stage biopharmaceutical company focused on the development of STAT3 inhibitors, today announced that its lead product, TTI-101, has been granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA) for the treatment of idiopathic pulmonary fibrosis (IPF). The …

Tvardi Therapeutics’ TTI-101 Receives Orphan Drug Designation for Idiopathic Pulmonary Fibrosis Read More »

Tvardi Therapeutics

Tvardi Therapeutics’ TTI-101 Receives Orphan Drug Designation for Hepatocellular Carcinoma

Press Releases / By

Houston, TX – April 21, 2022 – Tvardi Therapeutics, Inc. (“Tvardi”), a privately held, clinical-stage biopharmaceutical company focused on the development of STAT3 inhibitors, today announced that its lead product, TTI-101, has been granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA) for the treatment of hepatocellular carcinoma (HCC). The FDA …

Tvardi Therapeutics’ TTI-101 Receives Orphan Drug Designation for Hepatocellular Carcinoma Read More »

Data Demonstrating Tvardi’s TTI-101 Overcomes Palbociclib Resistance in Metastatic Breast Cancer Models to be Presented at the 2022 Annual Meeting of the American Association for Cancer Research

Press Releases / By

Houston, TX – April 7, 2022 – Tvardi Therapeutics, Inc. (“Tvardi”), a privately held, clinical-stage biopharmaceutical company focused on the development of STAT3 inhibitors, today announced its collaborators will present preclinical data demonstrating TTI-101 overcomes palbociclib resistance in metastatic breast cancer murine models at the upcoming 2022 Annual Meeting of the American Association for Cancer …

Data Demonstrating Tvardi’s TTI-101 Overcomes Palbociclib Resistance in Metastatic Breast Cancer Models to be Presented at the 2022 Annual Meeting of the American Association for Cancer Research Read More »

Nirogy Therapeutics Appoints Simon Pedder, Ph.D., as Chief Executive Officer

Press Releases / By

Appointment Strengthens Leadership and Expertise to Drive Lead Oncology Program into Phase 1 Clinical Development Founding Chief Executive Officer Dr. Vincent Sandanayaka transitions to role of President and Chief Scientific Officer Boston, Jan. 12, 2022 — Nirogy Therapeutics (“Nirogy” or “the Company”), a privately-held biotechnology company developing novel small molecules to target cellular transporters, today …

Nirogy Therapeutics Appoints Simon Pedder, Ph.D., as Chief Executive Officer Read More »

Sporos Bioventures Announces Formation of Strategic Advisory Board

Press Releases / By

Dr. Doug Williams to Chair SAB Inaugural members include Drs. Keith Flaherty, Bing Yao, and Doug Hanahan to advise on company’s growing pipeline and discovery engine HOUSTON, Texas., January 11, 2022 — Sporos Bioventures, LLC, (“Sporos” or the “Company”) a private biotechnology company catalyzing the rapid development of potential breakthrough therapies that target novel disease …

Sporos Bioventures Announces Formation of Strategic Advisory Board Read More »

Sporos Bioventures Appoints Dr. Rachel Humphrey to Board of Directors

Press Releases / By

HOUSTON–(BUSINESS WIRE)– Sporos Bioventures, LLC (“Sporos” or the “Company”), a private biotechnology company catalyzing the rapid development of breakthrough therapies through a portfolio of companies that target novel disease mechanisms in oncology and immune-related diseases, today announced the appointment of Rachel Humphrey, M.D. to its Board of Directors. “We are thrilled to welcome Rachel to …

Sporos Bioventures Appoints Dr. Rachel Humphrey to Board of Directors Read More »

Sporos Bioventures Appoints Amit Rakhit, M.D. as Chief Executive Officer

Press Releases / By

HOUSTON, Texas., September 29, 2021 — Sporos Bioventures, LLC, a private biotechnology company catalyzing the rapid development of breakthrough therapies through a portfolio of companies that target novel disease mechanisms in cancer, fibrosis, inflammation, and immune-related diseases, today announced the appointment of Amit Rakhit, M.D., M.B.A. as chief executive officer. Dr. Rakhit joins Sporos from …

Sporos Bioventures Appoints Amit Rakhit, M.D. as Chief Executive Officer Read More »

Scroll to Top